Entero Therapeutics (ENTO) Form 3: Director Jason Sawyer Reports No Shares

Jason D. Sawyer filed an Initial Form 3 under Section 16 reporting his relationship to Entero Therapeutics, Inc. (ENTO) as a Director.

Rhea-AI Filing Summary

Jason D. Sawyer filed an Initial Form 3 under Section 16 reporting his relationship to Entero Therapeutics, Inc. (ENTO) as a Director. The event date is 08/11/2025 and the form is signed on 08/18/2025. The filing discloses no securities beneficially owned by the reporting person, and no derivative holdings are listed.

Positive

• Initial Form 3 filed confirming compliance with Section 16 reporting requirements on 08/18/2025
• Reporting relationship disclosed as Director, providing clarity on insider status

Negative

• No securities beneficially owned reported, indicating no disclosed equity stake by the director
• No derivative holdings disclosed, so there are no immediate option-based incentives reported

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jason D. Sawyer report on the Form 3 for Entero Therapeutics (ENTO)?

He reported his status as a Director and signed the initial Form 3 on 08/18/2025, with the event date 08/11/2025.

Does the Form 3 show any shares owned by Jason D. Sawyer in ENTO?

No. The filing explicitly states no securities are beneficially owned by the reporting person.

Are there any derivative securities disclosed for Jason D. Sawyer on this Form 3?

No. Table II shows no derivative securities exercisable or outstanding for the reporting person.

What is the significance of filing a Form 3 for investors in ENTO?

A Form 3 establishes the reporting person's insider status (here, Director) and discloses any holdings; in this case it records no holdings as of the event date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2025 - 06:56 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sawyer Jason David

(Last) (First) (Middle)

C/O ENTERO THERAPEUTICS, INC.

777 YAMATO ROAD, SUITE 502

(Street)

BOCA RATON FL 33431

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
Entero Therapeutics, Inc. [ ENTO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jason D. Sawyer	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.